Antibiotic resistance develops when bacteria become less sensitive to antibiotics, rendering them less effective or ineffective at killing bacteria and treating infections. We urgently need new therapeutic strategies to combat...
Following an extensive laboratory and office improvement project in 2021, the company has further invested in facilities in Q4 2022.
The programme has involved undertaking extensive improvements of additional laboratories ens
Chris Bindon, Operations Director for Fixed Phage said:
Fixed Phage is committed to continuous improvement in our skills and training, facilities and capabilities through our core technology programme, professional development, and capital investment. These are key to scaling the company’s activities and continued success in the development and commercialisation of phage solutions and are fundamental to supporting our current and future programmes.
"New #funding has been made available by the Industrial #biotechnology Innovation Centre (IBioIC) to help grow Scotland’s BioTech economy with the latest tranche of its innovation fund now open for proposals." #scotland #biotech https://t.co/6Jdl5bgXbU